Guangyu Wu1, Huating Li1, Qichen Fang1, Shan Jiang1, Lei Zhang1, Jing Zhang1, Xuhong Hou1, Junxi Lu1, Yuqian Bao1, Aimin Xu1, Weiping Jia2. 1. From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China. 2. From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China. wpjia@sjtu.edu.cn.
Abstract
OBJECTIVE: Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of cardiovascular diseases (CVD). Lipocalin-2 (LCN2), mainly released from adipocytes, has been shown to be positively associated with CVD in cross-sectional studies. We aimed to evaluate the association of LCN2 with CVD involving a population-based cohort recruited from the Shanghai Diabetes Study. APPROACH AND RESULTS: Serum LCN2 levels were measured using ELISA. Independent predictors of CVD development were identified using Cox proportion hazards regression. The predictive performances of the various models were assessed by Kaplan-Meier analysis. At baseline, circulating LCN2 was significantly associated with a cluster of traditional cardiovascular risk factors. Baseline LCN2 levels in male subjects who developed CVD events during follow-up were significantly higher than those who did not develop CVD events (P=0.012). However, such difference was not significant in female subjects. LCN2 was a predictor of CVD in men, which remained statistically significant after adjustment for traditional cardiovascular risk factors (hazard ratio, 1.038 [95% confidence interval, 1.017-1.060]). LCN2 remained significantly associated with incident CVD even after adjustment for renal function, adiponectin, and high-sensitivity C-reactive protein levels. Kaplan-Meier analysis suggested combination of LCN2 and high-sensitivity C-reactive protein might improve the prediction of CVD events in male subjects. CONCLUSIONS: Elevated circulating LCN2 level is an independent predictor of CVD events in men in a population-based cohort and adds to the prognostic value of high-sensitivity C-reactive protein, which is currently the most extensively studied biomarker of CVD. Measurement of serum LCN2 might be useful for early detection and intervention of CVD.
OBJECTIVE: Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of cardiovascular diseases (CVD). Lipocalin-2 (LCN2), mainly released from adipocytes, has been shown to be positively associated with CVD in cross-sectional studies. We aimed to evaluate the association of LCN2 with CVD involving a population-based cohort recruited from the Shanghai Diabetes Study. APPROACH AND RESULTS: Serum LCN2 levels were measured using ELISA. Independent predictors of CVD development were identified using Cox proportion hazards regression. The predictive performances of the various models were assessed by Kaplan-Meier analysis. At baseline, circulating LCN2 was significantly associated with a cluster of traditional cardiovascular risk factors. Baseline LCN2 levels in male subjects who developed CVD events during follow-up were significantly higher than those who did not develop CVD events (P=0.012). However, such difference was not significant in female subjects. LCN2 was a predictor of CVD in men, which remained statistically significant after adjustment for traditional cardiovascular risk factors (hazard ratio, 1.038 [95% confidence interval, 1.017-1.060]). LCN2 remained significantly associated with incident CVD even after adjustment for renal function, adiponectin, and high-sensitivity C-reactive protein levels. Kaplan-Meier analysis suggested combination of LCN2 and high-sensitivity C-reactive protein might improve the prediction of CVD events in male subjects. CONCLUSIONS: Elevated circulating LCN2 level is an independent predictor of CVD events in men in a population-based cohort and adds to the prognostic value of high-sensitivity C-reactive protein, which is currently the most extensively studied biomarker of CVD. Measurement of serum LCN2 might be useful for early detection and intervention of CVD.
Authors: Milana Bogorodskaya; Kathleen V Fitch; Tricia H Burdo; Patrick Maehler; Rebecca M Easly; Gillian R Murray; Meghan Feldpausch; Gail K Adler; Steven K Grinspoon; Suman Srinivasa Journal: J Infect Dis Date: 2019-09-26 Impact factor: 5.226
Authors: Erfei Song; Sofhia V Ramos; Xiaojing Huang; Ying Liu; Amy Botta; Hye Kyoung Sung; Patrick C Turnbull; Michael B Wheeler; Thorsten Berger; Derek J Wilson; Christopher G R Perry; Tak W Mak; Gary Sweeney Journal: Proc Natl Acad Sci U S A Date: 2018-01-29 Impact factor: 11.205
Authors: Atlanta G I M Elie; Pia S Jensen; Katrine D Nissen; Ilvy M E Geraets; Aimin Xu; Erfei Song; Maria L Hansen; Akhmadjon Irmukhamedov; Lars M Rasmussen; Yu Wang; Jo G R De Mey Journal: PLoS One Date: 2016-05-03 Impact factor: 3.240